Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG0259 plus methotrexate in active rheumatoid arthritis with inadequate response to methotrexate
2009-015898-12Phase 2Completed
- Sponsor
- Lakefront Biotherapeutics
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GLPG-0259 in rheumatoid arthritis (RA) (4 arms), sponsored by Lakefront Biotherapeutics. Primary endpoint: ACR20 response rate at Week 12. Started Jun 2010; status: completed.
02
Drugs
GLPG-0259
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-015898-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015898-12.